Press Releases

Communiqué de presse - Sanofi renforce la bioproduction d’anticorps en France avec un investissement de plus de 40 millions d’euros sur son site de Lyon Gerland

Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria

Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma

Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis

Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance

Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI

Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare

Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines

Press Release: Sanofi in discussions to sell a controlling stake in Opella

Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants

Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD

Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD

Press Release: Availability of the Q3 2024 Aide mémoire

Media Update: EADV: New data reinforce Sanofi’s innovative approach and leadership across immune-mediated skin diseases

Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant

Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old

Press Release: Tolebrutinib demonstrated a 31% delay in time to onset of confirmed disability progression in non-relapsing secondary progressive multiple sclerosis phase 3 study

Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers

Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU

Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study